GLP-1 drugs could play surprising role in cancer risk and outcomes
As GLP-1 medications continue reshaping the treatment of obesity and diabetes, researchers are also investigating whether the drugs could influence cancer risk and outcomes. The American Association for Cancer Research’s 2026 Cancer Progress Report, released earlier this month, noted that obesity is a major risk factor for many cancers. As glucagon-like peptide-1 medications – including … Read more